GSK to Cut Up to 1,217 Jobs in Belgium in Three-Year Overhaul

GSK plans to cut up to 1,217 jobs in Belgium, Reuters reported, as the British pharmaceutical company begins a three-year restructuring plan. That figure makes Belgium the first market where the program's scale has a firm number attached.

The cuts land in one of Europe's strongest pharma manufacturing bases. Belgium hosts a dense cluster of drug production and R&D operations. A reduction of this size in a single country signals that the restructuring will touch operational roles, not just corporate overhead.

What do we know so far?

The confirmed facts are narrow but concrete:

• Up to 1,217 positions affected in Belgium.
• The restructuring runs on a three-year timeline.
• GSK has begun the program; Belgium marks the opening move.
• Reuters has reported the figures; company-wide totals haven't been disclosed yet.

"Up to" matters here. It's a ceiling, not a final count. In practice, negotiated packages, attrition and internal redeployment can pull the real number below the headline figure. Workers covered by Belgian collective bargaining agreements (sector-wide labor contracts) typically get notice periods and transition support that shape how cuts actually land.

How big is this for GSK's Belgian workforce?

GSK hasn't published the size of its Belgian headcount alongside the announcement, so the layoff-to-workforce ratio can't be calculated yet. What's clear is the duration. A three-year window spreads the reductions out. That pacing usually means phased site-level consultations rather than a single mass layoff event.

For pharma professionals in Belgium, the signal is direct. Manufacturing and support roles at GSK Belgian sites now carry restructuring risk over a known horizon. Job seekers in the region should treat the next 36 months as a period when an unusually large pool of experienced pharma workers may re-enter the local market — a supply shift that affects wage bargaining power for comparable roles at competitors.

What happens next?

Expect works council negotiations (formal employee-representative consultations required under Belgian law) to refine the 1,217 figure site by site. Further country-level announcements are plausible as the three-year plan rolls out. Reuters will remain the primary outlet tracking confirmed numbers as GSK discloses them.